

**AHNCI Urologic Oncology Program Tumor Board**

Wednesday, May 27, 2020

5:00-6:00 p.m.

<https://zoom.us/j/93034036822>

Dial – 1-646-558-8656

Meeting ID: 930 3403 6822

**Password: 755592**

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case** | **De-identified patient** | **Reason** | **Presenter** |
| 1 | RS MRN: 10708330 | 69M s/p RPPLND 2010 grade group III SM- pT2cN0. S/p salvage XRT with ADT in 2013. Slowly rising PSA starting in 2016, currently 1.8 as of March 2020. Bone scan suggested T10 lesion. Axumin PET shows no avidity in T10 but shows mildly avid peri-rectal node. Next steps for workup/management? | ZH |
| 2 | JL MRN: 4911995 | Prostate Cancer, imaging review only | JL |
| 3 | VH MRN: 4366073 | adrenal mass, renal cell cancer, imaging review only | JL |
| 4 | JR MRN: 8369 | Prostate ca, Local reoccurrence in bladder, requesting radiology review 4/28/20 scans. Questioning Biopsy or Radiation | SM |
| 5 | JZ MRN:  542966 | Metastatic Renal ca, requesting radiology review Ct on 5/16/20  Question if pt for Nephrectomy | GF |
| 6 | DC MRN: 2031904 | Prostate ca   HX of EBRT and rising PSA, requesting radiology review 5/19/20 review Pet. Questioning value of a Pelvic MRI and/or cryo | SM |
| 7 | PJ MRN: 5005118 | Metastatic renal ca. Hypermetabolic mass next to Prostate, Had XRT to the R Seminole Vesicle, requesting radiology review 1/2020 pet scan, Can anything else be done Locally? | SM |
| 8 | CG MRN: 10500256 | Reason for Discussion: Metastatic Prostate CA currently on ADH+abiraterone. Prostate mass with potential bladder invasion. Treatment/surveillance options?? | SA |
| 9 | EP MRN: 11949795 | Malignant neoplasm of posterior wall of urinary bladder, requesting review of most recent PET/CT—to discuss radical cystectomy +/- adjuvant chemotherapy | MI |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–  
will use this **same** number every week to text your attendance

**Today’s SMS Code: QEXHUV**

You must text within 24 hours of the start of tumor board. You will receive a text receipt and a link to confirm attendance and receive credit

Objectives: Upon completion of this activity, participants will have a better understanding of decision-making for complex Urologic Oncology and be armed with clinical pathways to improve care.

Accreditation: Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement:Allegheny General Hospital designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)™*.  Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Disclosure: In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators and Presenters: Russell Fuhrer MD, Ralph Miller MD, Shifeng Mao MD has nothing to disclose